RU2332999C2 - Терапевтические способы и применения сапогенинов и их производных - Google Patents

Терапевтические способы и применения сапогенинов и их производных Download PDF

Info

Publication number
RU2332999C2
RU2332999C2 RU2004130281/15A RU2004130281A RU2332999C2 RU 2332999 C2 RU2332999 C2 RU 2332999C2 RU 2004130281/15 A RU2004130281/15 A RU 2004130281/15A RU 2004130281 A RU2004130281 A RU 2004130281A RU 2332999 C2 RU2332999 C2 RU 2332999C2
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
acceptable salts
glucose
disease
smilagenin
Prior art date
Application number
RU2004130281/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004130281A (ru
Inventor
Дарэл РИС
Фил Ганнинг
Антония Орси
Зонгкин Ксиа
Яар ХУ
Original Assignee
ФИТОФАРМ ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP020101170A external-priority patent/AR033079A1/es
Application filed by ФИТОФАРМ ПиЭлСи filed Critical ФИТОФАРМ ПиЭлСи
Publication of RU2004130281A publication Critical patent/RU2004130281A/ru
Application granted granted Critical
Publication of RU2332999C2 publication Critical patent/RU2332999C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
RU2004130281/15A 2002-03-27 2003-03-27 Терапевтические способы и применения сапогенинов и их производных RU2332999C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ARP020101170 2002-03-27
ARP020101170A AR033079A1 (es) 2001-03-28 2002-03-27 Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso
US36817802P 2002-03-28 2002-03-28
GBPCT/GB02/01578 2002-03-28
US60/368178 2002-03-28
PCT/GB2002/001578 WO2002079221A2 (fr) 2001-03-28 2002-03-28 Derives de sapogenine, synthese et utilisation correspondantes et procedes fondes sur leur utilisation

Publications (2)

Publication Number Publication Date
RU2004130281A RU2004130281A (ru) 2006-01-20
RU2332999C2 true RU2332999C2 (ru) 2008-09-10

Family

ID=30001210

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004130281/15A RU2332999C2 (ru) 2002-03-27 2003-03-27 Терапевтические способы и применения сапогенинов и их производных

Country Status (10)

Country Link
KR (1) KR20100093621A (fr)
CN (1) CN1642558B (fr)
AT (1) ATE424211T1 (fr)
IL (1) IL164161A0 (fr)
NZ (2) NZ547344A (fr)
PE (1) PE20040306A1 (fr)
PL (1) PL213697B1 (fr)
RU (1) RU2332999C2 (fr)
TW (1) TWI329016B (fr)
WO (1) WO2003082893A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861788B2 (en) * 2003-06-03 2005-03-01 Motorola, Inc. Switchable display/mirror method and apparatus
FR2868700B1 (fr) * 2004-04-09 2008-09-26 Michel Coisy Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie.
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) * 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
US20090041865A1 (en) 2005-10-28 2009-02-12 Sun-Yeou Kim Extract of the Family Dioscoreaceae and Composition for Preventing or Treating Peripheral Neuropathy Comprising the Same
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CN103189056A (zh) 2010-07-20 2013-07-03 植物药物公共有限公司 L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
WO2013149580A1 (fr) * 2012-04-03 2013-10-10 Chiming Che Composés timosaponine
WO2014160480A1 (fr) 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Stéroïdes neuroactifs et leurs procédés d'utilisation
CN103232520A (zh) * 2013-05-13 2013-08-07 中国药科大学 一种螺甾类化合物、其制备方法及医药用途
EP4306114A1 (fr) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4316591A3 (fr) 2015-07-06 2024-04-24 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
IL305404A (en) 2015-07-06 2023-10-01 Sage Therapeutics Inc Oxysterols and methods of using them
BR112018070123A2 (pt) 2016-04-01 2019-02-05 Sage Therapeutics Inc oxiesterós e métodos de uso dos mesmos
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
CA3029900A1 (fr) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols et leurs methodes d'utilisation
EP3519422B1 (fr) 2016-09-30 2022-08-31 Sage Therapeutics, Inc. Oxystérols substitués en c7 et ces composés pour l'utilisation en tant que modulateurs nmda
AU2017345399B2 (en) 2016-10-18 2022-02-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN108264535A (zh) 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
RU2635485C1 (ru) * 2017-03-21 2017-11-13 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения атрофии зрительного нерва после черепно-мозговой травмы
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
EP3572085A1 (fr) * 2018-05-25 2019-11-27 Neuro-Sys Composition de combinaison synergétique comprenant une saponine stéroïdique, premier composé polyphénolique et éventuellement, second composé polyphénolique
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3416112A1 (de) * 1984-04-30 1985-10-31 Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
TW479061B (en) * 1993-12-24 2002-03-11 Mitsubishi Chem Corp Sialic acid derivatives
JPH092957A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 末梢性神経障害の治療、予防薬
JPH092956A (ja) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp 神経障害の治療、予防薬
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
EP1066033B1 (fr) * 1998-03-26 2005-12-28 Phytopharm Plc Smilagenine et anzurogenine d et leur utilisation
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
JP2002030096A (ja) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd 神経細胞突起再生剤及びその製造方法
CA2479249A1 (fr) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc. Compositions pharmaceutiques neuroprotectrices a base de spirostenol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ХАРКЕВИЧ Д.А. Фармакология. - М.: Медицина, 1987, с.47-48. БЕЛИКОВ В.Г. Фармацевтическая химия. - М.: Высшая школа, 1993, т.1, с.43-47. *

Also Published As

Publication number Publication date
CN1642558B (zh) 2012-05-30
PE20040306A1 (es) 2004-05-29
PL372941A1 (en) 2005-08-08
RU2004130281A (ru) 2006-01-20
KR20100093621A (ko) 2010-08-25
CN1642558A (zh) 2005-07-20
PL213697B1 (pl) 2013-04-30
WO2003082893A2 (fr) 2003-10-09
WO2003082893A8 (fr) 2003-12-31
ATE424211T1 (de) 2009-03-15
TWI329016B (en) 2010-08-21
WO2003082893A3 (fr) 2004-04-15
NZ547344A (en) 2007-11-30
NZ547897A (en) 2008-02-29
IL164161A0 (en) 2005-12-18
TW200400042A (en) 2004-01-01

Similar Documents

Publication Publication Date Title
RU2332999C2 (ru) Терапевтические способы и применения сапогенинов и их производных
Melcangi et al. Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: Sex-specific features
Luoma et al. Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone-mediated neuroprotection
WO2007133673A3 (fr) Procédés de traitement d&#39;un trouble neurologique avec du monohydrate de créatine
PH12020550631A1 (en) New catecholamine prodrugs for use in the treatment of parkinson`s disease
WO2004110389A3 (fr) Ligands des recepteurs sigma pour regeneration neuronale et retablissement fonctionnel
US20110190249A1 (en) Therapeutic methods and uses of sapogenins and their derivatives
BR112012007580A2 (pt) conjunto para um dispositivo de distribuição de fármaco
MX2011013258A (es) Proteinas de fusion para entrega de gdnf y bdnf al sistema nervioso central.
CA2986891C (fr) Compositions et methodes pour le traitement de la maladie de parkinson et de troubles associes
EA200800767A1 (ru) Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им патологических состояний
Garcia et al. Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation
EP1255556A4 (fr) Utilisations a des fins neuroprotectrices, antithrombotiques et anti-inflammatoires de la proteine c activee
WO2007053580A3 (fr) Ligands du recepteur sigma utilises pour la regeneration neuronale et la recuperation fonctionnelle
EP2774661A3 (fr) Mâchoire avant pour une fixation de ski de randonnée
WO2008057609A4 (fr) Procédés de traitement de troubles neuronaux à l&#39;aide de peptides mntf et de leurs analogues
BR112015021333A2 (pt) conjunto para um dispositivo de aplicação de fármaco
BR112021021184A8 (pt) Fármaco terapêutico para discinesia
PT98427A (pt) Metodo para tratamento de doencas do sistema nervoso central com compostos amino-alcoois heterociclicos
US20050130948A1 (en) Therapeutic methods and uses of sapogenins and their derivatives
RU2008110392A (ru) Терапевтические способы и применения сапогенинов и их производных
CA2477787A1 (fr) Methodes therapeutiques et utilisations des sapogenines et de leurs derives
DE60118418T2 (de) Maurotoxin, pi1 und hstx1 derivate
WO2014068171A1 (fr) 4-aminophénols n-substitués et quinones imines correspondantes
Jamal et al. Dual neuroprotective role of Hsp2 against α-Synuclein aggregates

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090328